DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
BIBF1120 is an investigational drug.
There have been 18 clinical trials for BIBF1120. The most recent clinical trial was a Phase 3 trial, which was initiated on December 1st 2008.
The most common disease conditions in clinical trials are Carcinoma, Ovarian Neoplasms, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are Boehringer Ingelheim, European Organisation for Research and Treatment of Cancer - EORTC, and M.D. Anderson Cancer Center.
Recent Clinical Trials for BIBF1120
|Ph II Nintedanib or Intravenous Ifosfamide Advanced Metastatic STS Failed on Imatinib and Sunitinib||Boehringer Ingelheim||Phase 2|
|Ph II Nintedanib or Intravenous Ifosfamide Advanced Metastatic STS Failed on Imatinib and Sunitinib||European Organisation for Research and Treatment of Cancer - EORTC||Phase 2|
|Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors||Boehringer Ingelheim||Phase 1|